April 5: The Week in Cancer News
More cancer patients are enrolling in clinical trials, and sentinel node biopsies alone may be adequate for some early-stage breast cancers.
Progress Against Cancer
More cancer patients are enrolling in clinical trials, and sentinel node biopsies alone may be adequate for some early-stage breast cancers.
Fam-trastuzumab deruxtecan-nxki was approved for HER2-positive tumors, regardless of the tissue of origin. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu) for adult patients with unresectable...
The recently approved immunotherapy Amtagvi uses a patient’s own immune cells to destroy advanced melanoma.
March's picks include how synergy drives drug resistance in AML, new early detection tools, and more.
First CAR T-cell therapy approval in chronic lymphocytic leukemia, and Environmental Protection Agency announces a complete ban on asbestos use in manufacturing.
Mirvetuximab soravtansine-gynx was approved for certain ovarian, fallopian tube, and peritoneal cancers. The U.S. Food and Drug Administration (FDA) has approved mirvetuximab soravtansine-gynx (Elaher) for patients with ovarian epithelial, fallopian tube, or peritoneal cancers...
Three patients share their experiences about having Lynch syndrome.
Improvements in medical care have reduced the rate of relapse in acute myeloid leukemia after transplants, helped people live longer, and reduced mortality from other causes, according to large set of data. Older patients...
Researchers are exploring new options for kidney cancer treatments.
The BCR-ABL inhibitor ponatinib was approved for some patients with acute lymphoblastic leukemia. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to ponatinib (Iclusig) in combination with chemotherapy for adult patients...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More